Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexidol in children with ADHD
NCT06854601Phase 3Completed
- Sponsor
- Pharmasoft
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of emoxypine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Pharmasoft. Primary endpoint: Average Change in the Total Score Across the Inattention and Hyperactivity/Impulsivity Subscales of the Swanson, Nolan and Pelham Teacher and Parent Rating Scale at 6 weeks. Started Jul 2019; status: completed.
02
Drugs
emoxypine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06854601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06854601.